Liver shunt may boost outcomes in cancer patients on immunotherapy
NCT ID NCT07365930
First seen Jan 30, 2026 · Last updated Jun 12, 2026 · Updated 27 times
Summary
This study looks at whether a procedure called TIPS (a shunt placed in the liver to reduce pressure) helps people with liver cancer who are taking the drugs atezolizumab and bevacizumab. About 350 participants will be observed to see how their liver function, survival, and quality of life change over time. The goal is to understand if adding TIPS improves outcomes in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital of Düsseldorf
RECRUITINGDüsseldorf, North Rhine-Westphalia, 40225, Germany
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.